Deborah W. Alexander, Md, Pa | |
801 E Nolana, Suite 6, Mcallen, TX 78504-6113 | |
(956) 683-1500 | |
(956) 683-1502 |
Full Name | Deborah W. Alexander, Md, Pa |
---|---|
Type | Facility |
Speciality | Ophthalmology |
Location | 801 E Nolana, Mcallen, Texas |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013001569 | NPI | - | NPPES |
0035NP | Other | TX | BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Primary |
207W00000X | Ophthalmology | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Deborah W. Alexander, Md, Pa 801 E Nolana, Suite 6, Mcallen, TX 78504-6113 Ph: (956) 683-1500 | Deborah W. Alexander, Md, Pa 801 E Nolana, Suite 6, Mcallen, TX 78504-6113 Ph: (956) 683-1500 |
News Archive
Kids who get migraine headaches are much more likely than other children to also have behavioral difficulties, including social and attention issues, and anxiety and depression. The more frequent the headaches, the greater the effect, according to research out now in the journal Cephalagia, published by SAGE.
A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.
Two community dental clinics that provide much-needed services to low-income people who lack access to care will receive a $10,000 grant from Delta Dental of Pennsylvania.
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.
› Verified 2 days ago